Although sCD163 plasmatic level is not a routine evaluation in COVID-19 patients, all these reports suggest that sCD163 plasmatic levels could represent a useful and easily assessable biomarker of disease progression underlining its clinical utility. Here, CD163 is linked to COVID-19.